Skip to main content
Top
Published in: Inflammation 2/2014

01-04-2014

Identification of Inflamed Atherosclerotic Lesions In Vivo Using PET-CT

Authors: Mateja Kaja Jezovnik, Nina Zidar, Luka Lezaic, Borut Gersak, Pavel Poredos

Published in: Inflammation | Issue 2/2014

Login to get access

Abstract

Inflammation plays a major pathogenetic role in the development of atherosclerotic plaques and related thromboembolic events. The identification of vulnerable plaques is of the utmost importance, as this may allow the implementation of more effective preventive and therapeutic interventions. Fluorodeoxyglucose positron emission tomography (FDG-PET) has been shown to be useful for tracing inflammation within plaques. However, its relationship to immunohistochemical findings in different territories of the peripheral circulation was not completely elucidated. We aimed to determine whether plaque inflammation could be measured by PET in combination with computer tomography (CT) using FDG and what is the relationship between FDG uptake and immunohistochemical findings in the removed atherosclerotic lesions of the femoral and carotid arteries. The study included 31 patients, 21 patients with high-grade stenosis of the internal carotid artery (ICA) and 10 patients with occlusion of the common femoral artery (CFA), all of whom underwent endarterectomy. Before endarterectomy in all patients, FDG-PET/CT imaging was performed. FDG uptake was measured as the maximum blood—normalized standardized uptake value, known as the target to background ratio (TBR max). TBR max amounted to 1.72 ± 0.8, and in patients with ICA, stenosis was not significantly different from patients with CFA occlusion. Immunohistochemical and morphometric analyses of the plaques obtained at endarterectomy showed that the density of T lymphocytes and macrophages (number of cells per square millimeter) was significantly higher in subjects with stenosis of the ICA than in subjects with occlusion of the femoral arteries: lymphocytes, 1.26 ± 0.21 vs. 0.77 ± 0.29; p = 0.02 and macrophages, 1.01 ± 0.18 vs. 0.69 ± 0.23; p = 0.003. In the whole group of patients, the density of inflammatory cells significantly correlated with FDG uptake represented by PET-TBR max: T lymphocytes, r = 0.60; p < 0.01 and macrophages, r = 0.65; p < 0.01. The results of our study show that FDG uptake is related to the accumulation of inflammatory cells in atherosclerotic lesions. This finding suggests that FDG uptake reflects the severity of atherosclerotic vessel wall inflammation, and in stenotic lesions, it could be an indicator of their vulnerability. However, data from large outcome studies is needed to estimate the usefulness of this technique in identifying the most dangerous atherosclerotic lesions and vulnerable patients.
Literature
1.
go back to reference Grundy, S.M., J.I. Cleeman, C.N. Merz, H.B. Brewer, L.T. Clark, D.B. Hunninghake, R.C. Pasternak, S.C. Smith, N.J. Stone, National Heart Ln, and Blood Institute, Foundation ACoC, and Association AH. 2004. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110: 227–239.PubMedCrossRef Grundy, S.M., J.I. Cleeman, C.N. Merz, H.B. Brewer, L.T. Clark, D.B. Hunninghake, R.C. Pasternak, S.C. Smith, N.J. Stone, National Heart Ln, and Blood Institute, Foundation ACoC, and Association AH. 2004. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110: 227–239.PubMedCrossRef
2.
go back to reference Naghavi, M., P. Libby, E. Falk, S.W. Casscells, S. Litovsky, J. Rumberger, J.J. Badimon, C. Stefanadis, P. Moreno, G. Pasterkamp, Z. Fayad, P.H. Stone, S. Waxman, P. Raggi, M. Madjid, A. Zarrabi, A. Burke, C. Yuan, P.J. Fitzgerald, D.S. Siscovick, C.L. de Korte, M. Aikawa, K.E. Juhani Airaksinen, G. Assmann, C.R. Becker, J.H. Chesebro, A. Farb, Z.S. Galis, C. Jackson, I.K. Jang, W. Koenig, R.A. Lodder, K. March, J. Demirovic, M. Navab, S.G. Priori, M.D. Rekhter, R. Bahr, S.M. Grundy, R. Mehran, A. Colombo, E. Boerwinkle, C. Ballantyne, W. Insull, R.S. Schwartz, R. Vogel, P.W. Serruys, G.K. Hansson, D.P. Faxon, S. Kaul, H. Drexler, P. Greenland, J.E. Muller, R. Virmani, P.M. Ridker, D.P. Zipes, P.K. Shah, and J.T. Willerson. 2003. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 108: 1664–1672.PubMedCrossRef Naghavi, M., P. Libby, E. Falk, S.W. Casscells, S. Litovsky, J. Rumberger, J.J. Badimon, C. Stefanadis, P. Moreno, G. Pasterkamp, Z. Fayad, P.H. Stone, S. Waxman, P. Raggi, M. Madjid, A. Zarrabi, A. Burke, C. Yuan, P.J. Fitzgerald, D.S. Siscovick, C.L. de Korte, M. Aikawa, K.E. Juhani Airaksinen, G. Assmann, C.R. Becker, J.H. Chesebro, A. Farb, Z.S. Galis, C. Jackson, I.K. Jang, W. Koenig, R.A. Lodder, K. March, J. Demirovic, M. Navab, S.G. Priori, M.D. Rekhter, R. Bahr, S.M. Grundy, R. Mehran, A. Colombo, E. Boerwinkle, C. Ballantyne, W. Insull, R.S. Schwartz, R. Vogel, P.W. Serruys, G.K. Hansson, D.P. Faxon, S. Kaul, H. Drexler, P. Greenland, J.E. Muller, R. Virmani, P.M. Ridker, D.P. Zipes, P.K. Shah, and J.T. Willerson. 2003. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. Circulation 108: 1664–1672.PubMedCrossRef
3.
go back to reference Schwartz, S.M., Z.S. Galis, M.E. Rosenfeld, and E. Falk. 2007. Plaque rupture in humans and mice. Arteriosclerosis, Thrombosis, and Vascular Biology 27: 705–713.PubMedCrossRef Schwartz, S.M., Z.S. Galis, M.E. Rosenfeld, and E. Falk. 2007. Plaque rupture in humans and mice. Arteriosclerosis, Thrombosis, and Vascular Biology 27: 705–713.PubMedCrossRef
4.
go back to reference Bogiatzi, C., M.S. Cocker, R. Beanlands, and J.D. Spence. 2012. Identifying high-risk asymptomatic carotid stenosis. Expert Opinion on Medical Diagnostics 6: 139–151.PubMedCrossRef Bogiatzi, C., M.S. Cocker, R. Beanlands, and J.D. Spence. 2012. Identifying high-risk asymptomatic carotid stenosis. Expert Opinion on Medical Diagnostics 6: 139–151.PubMedCrossRef
5.
go back to reference Rudd, J.H., K.S. Myers, S. Bansilal, J. Machac, C.A. Pinto, C. Tong, A. Rafique, R. Hargeaves, M. Farkouh, V. Fuster, and Z.A. Fayad. 2008. Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. Journal of Nuclear Medicine 49: 871–878.PubMedCrossRef Rudd, J.H., K.S. Myers, S. Bansilal, J. Machac, C.A. Pinto, C. Tong, A. Rafique, R. Hargeaves, M. Farkouh, V. Fuster, and Z.A. Fayad. 2008. Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations. Journal of Nuclear Medicine 49: 871–878.PubMedCrossRef
6.
go back to reference Hubalewska-Dydejczyk, A., T. Stompór, M. Kalembkiewicz, M. Krzanowski, R. Mikolajczak, A. Sowa-Staszczak, B. Tabor-Ciepiela, U. Karczmarczyk, B. Kusnierz-Cabala, and W. Sulowicz. 2009. Identification of inflamed atherosclerotic plaque using 123 I-labeled interleukin-2 scintigraphy in high-risk peritoneal dialysis patients: a pilot study. Peritoneal Dialysis International 29: 568–574.PubMed Hubalewska-Dydejczyk, A., T. Stompór, M. Kalembkiewicz, M. Krzanowski, R. Mikolajczak, A. Sowa-Staszczak, B. Tabor-Ciepiela, U. Karczmarczyk, B. Kusnierz-Cabala, and W. Sulowicz. 2009. Identification of inflamed atherosclerotic plaque using 123 I-labeled interleukin-2 scintigraphy in high-risk peritoneal dialysis patients: a pilot study. Peritoneal Dialysis International 29: 568–574.PubMed
7.
go back to reference Ridker, P.M., N. Rifai, M. Clearfield, J.R. Downs, S.E. Weis, J.S. Miles, and A.M. Gotto. 2001. Investigators AFTCAPS: measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. New England Journal of Medicine 344: 1959–1965.PubMedCrossRef Ridker, P.M., N. Rifai, M. Clearfield, J.R. Downs, S.E. Weis, J.S. Miles, and A.M. Gotto. 2001. Investigators AFTCAPS: measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. New England Journal of Medicine 344: 1959–1965.PubMedCrossRef
8.
go back to reference Nighoghossian, N., L. Derex, and P. Douek. 2005. The vulnerable carotid artery plaque: current imaging methods and new perspectives. Stroke 36: 2764–2772.PubMedCrossRef Nighoghossian, N., L. Derex, and P. Douek. 2005. The vulnerable carotid artery plaque: current imaging methods and new perspectives. Stroke 36: 2764–2772.PubMedCrossRef
9.
go back to reference Blockmans, D., A. Maes, S. Stroobants, J. Nuyts, G. Bormans, D. Knockaert, H. Bobbaers, and L. Mortelmans. 1999. New arguments for a vasculitic nature of polymyalgia rheumatica using positron emission tomography. Rheumatology (Oxford) 38: 444–447.CrossRef Blockmans, D., A. Maes, S. Stroobants, J. Nuyts, G. Bormans, D. Knockaert, H. Bobbaers, and L. Mortelmans. 1999. New arguments for a vasculitic nature of polymyalgia rheumatica using positron emission tomography. Rheumatology (Oxford) 38: 444–447.CrossRef
10.
go back to reference Tawakol, A., R.Q. Migrino, G.G. Bashian, S. Bedri, D. Vermylen, R.C. Cury, D. Yates, G.M. LaMuraglia, K. Furie, S. Houser, H. Gewirtz, J.E. Muller, T.J. Brady, and A.J. Fischman. 2006. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. Journal of the American College of Cardiology 48: 1818–1824.PubMedCrossRef Tawakol, A., R.Q. Migrino, G.G. Bashian, S. Bedri, D. Vermylen, R.C. Cury, D. Yates, G.M. LaMuraglia, K. Furie, S. Houser, H. Gewirtz, J.E. Muller, T.J. Brady, and A.J. Fischman. 2006. In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. Journal of the American College of Cardiology 48: 1818–1824.PubMedCrossRef
11.
go back to reference Mehta, N.N., D.A. Torigian, J.M. Gelfand, B. Saboury, and A. Alavi. 2012. Quantification of atherosclerotic plaque activity and vascular inflammation using [18-F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT). J Vis Exp 63: 3777.PubMed Mehta, N.N., D.A. Torigian, J.M. Gelfand, B. Saboury, and A. Alavi. 2012. Quantification of atherosclerotic plaque activity and vascular inflammation using [18-F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT). J Vis Exp 63: 3777.PubMed
12.
go back to reference Rudd, J.H., E.A. Warburton, T.D. Fryer, H.A. Jones, J.C. Clark, N. Antoun, P. Johnström, A.P. Davenport, P.J. Kirkpatrick, B.N. Arch, J.D. Pickard, and P.L. Weissberg. 2002. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 105: 2708–2711.PubMedCrossRef Rudd, J.H., E.A. Warburton, T.D. Fryer, H.A. Jones, J.C. Clark, N. Antoun, P. Johnström, A.P. Davenport, P.J. Kirkpatrick, B.N. Arch, J.D. Pickard, and P.L. Weissberg. 2002. Imaging atherosclerotic plaque inflammation with [18F]-fluorodeoxyglucose positron emission tomography. Circulation 105: 2708–2711.PubMedCrossRef
13.
go back to reference Tahara, N., H. Kai, S. Yamagishi, M. Mizoguchi, H. Nakaura, M. Ishibashi, H. Kaida, K. Baba, N. Hayabuchi, and T. Imaizumi. 2007. Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. Journal of the American College of Cardiology 49: 1533–1539.PubMedCrossRef Tahara, N., H. Kai, S. Yamagishi, M. Mizoguchi, H. Nakaura, M. Ishibashi, H. Kaida, K. Baba, N. Hayabuchi, and T. Imaizumi. 2007. Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. Journal of the American College of Cardiology 49: 1533–1539.PubMedCrossRef
14.
go back to reference Graebe, M., S.F. Pedersen, L. Borgwardt, L. Højgaard, H. Sillesen, and A. Kjaer. 2009. Molecular pathology in vulnerable carotid plaques: correlation with [18]-fluorodeoxyglucose positron emission tomography (FDG-PET). European Journal of Vascular and Endovascular Surgery 37: 714–721.PubMedCrossRef Graebe, M., S.F. Pedersen, L. Borgwardt, L. Højgaard, H. Sillesen, and A. Kjaer. 2009. Molecular pathology in vulnerable carotid plaques: correlation with [18]-fluorodeoxyglucose positron emission tomography (FDG-PET). European Journal of Vascular and Endovascular Surgery 37: 714–721.PubMedCrossRef
15.
go back to reference Daugherty, A., and D.L. Rateri. 2002. T lymphocytes in atherosclerosis: the yin-yang of Th1 and Th2 influence on lesion formation. Circulation Research 90: 1039–1040.PubMedCrossRef Daugherty, A., and D.L. Rateri. 2002. T lymphocytes in atherosclerosis: the yin-yang of Th1 and Th2 influence on lesion formation. Circulation Research 90: 1039–1040.PubMedCrossRef
16.
go back to reference Bushart, G.B., U. Vetter, and W. Hartmann. 1993. Glucose transport during cell cycle in IM9 lymphocytes. Hormone and Metabolic Research 25: 210–213.PubMedCrossRef Bushart, G.B., U. Vetter, and W. Hartmann. 1993. Glucose transport during cell cycle in IM9 lymphocytes. Hormone and Metabolic Research 25: 210–213.PubMedCrossRef
17.
go back to reference Shozushima, M., R. Tsutsumi, K. Terasaki, S. Sato, R. Nakamura, and K. Sakamaki. 2003. Augmentation effects of lymphocyte activation by antigen-presenting macrophages on FDG uptake. Annals of Nuclear Medicine 17: 555–560.PubMedCrossRef Shozushima, M., R. Tsutsumi, K. Terasaki, S. Sato, R. Nakamura, and K. Sakamaki. 2003. Augmentation effects of lymphocyte activation by antigen-presenting macrophages on FDG uptake. Annals of Nuclear Medicine 17: 555–560.PubMedCrossRef
18.
go back to reference Gallagher, B.M., J.S. Fowler, N.I. Gutterson, R.R. MacGregor, C.N. Wan, and A.P. Wolf. 1978. Metabolic trapping as a principle of oradiopharmaceutical design: some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-d-glucose. Journal of Nuclear Medicine 19: 1154–1161.PubMed Gallagher, B.M., J.S. Fowler, N.I. Gutterson, R.R. MacGregor, C.N. Wan, and A.P. Wolf. 1978. Metabolic trapping as a principle of oradiopharmaceutical design: some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-d-glucose. Journal of Nuclear Medicine 19: 1154–1161.PubMed
19.
go back to reference Menezes, L.J., C.W. Kotze, O. Agu, T. Richards, J. Brookes, V.J. Goh, M. Rodriguez-Justo, R. Endozo, R. Harvey, S.W. Yusuf, P.J. Ell, and A.M. Groves. 2011. Investigating vulnerable atheroma using combined (18)F-FDG PET/CT angiography of carotid plaque with immunohistochemical validation. Journal of Nuclear Medicine 52: 1698–1703.PubMedCrossRef Menezes, L.J., C.W. Kotze, O. Agu, T. Richards, J. Brookes, V.J. Goh, M. Rodriguez-Justo, R. Endozo, R. Harvey, S.W. Yusuf, P.J. Ell, and A.M. Groves. 2011. Investigating vulnerable atheroma using combined (18)F-FDG PET/CT angiography of carotid plaque with immunohistochemical validation. Journal of Nuclear Medicine 52: 1698–1703.PubMedCrossRef
20.
go back to reference Rudd, J.H., F. Hyafil, and Z.A. Fayad. 2009. Inflammation imaging in atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 29: 1009–1016.PubMedCentralPubMedCrossRef Rudd, J.H., F. Hyafil, and Z.A. Fayad. 2009. Inflammation imaging in atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology 29: 1009–1016.PubMedCentralPubMedCrossRef
21.
go back to reference Cocker, M.S., B. Mc Ardle, J.D. Spence, C. Lum, R.R. Hammond, D.C. Ongaro, M.A. McDonald, R.A. Dekemp, J.C. Tardif, and R.S. Beanlands. 2012. Imaging atherosclerosis with hybrid [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography imaging: what Leonardo da Vinci could not see. Journal of Nuclear Cardiology 19: 1211–1225.PubMedCentralPubMedCrossRef Cocker, M.S., B. Mc Ardle, J.D. Spence, C. Lum, R.R. Hammond, D.C. Ongaro, M.A. McDonald, R.A. Dekemp, J.C. Tardif, and R.S. Beanlands. 2012. Imaging atherosclerosis with hybrid [(18)F]fluorodeoxyglucose positron emission tomography/computed tomography imaging: what Leonardo da Vinci could not see. Journal of Nuclear Cardiology 19: 1211–1225.PubMedCentralPubMedCrossRef
22.
go back to reference Arauz, A., L. Hoyos, M. Zenteno, R. Mendoza, and E. Alexanderson. 2007. Carotid plaque inflammation detected by 18F-fluorodeoxyglucose-positron emission tomography. Pilot study. Clinical Neurology and Neurosurgery 109: 409–412.PubMedCrossRef Arauz, A., L. Hoyos, M. Zenteno, R. Mendoza, and E. Alexanderson. 2007. Carotid plaque inflammation detected by 18F-fluorodeoxyglucose-positron emission tomography. Pilot study. Clinical Neurology and Neurosurgery 109: 409–412.PubMedCrossRef
23.
go back to reference Rominger, A., T. Saam, S. Wolpers, C.C. Cyran, M. Schmidt, S. Foerster, K. Nikolaou, M.F. Reiser, P. Bartenstein, and M. Hacker. 2009. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. Journal of Nuclear Medicine 50: 1611–1620.PubMedCrossRef Rominger, A., T. Saam, S. Wolpers, C.C. Cyran, M. Schmidt, S. Foerster, K. Nikolaou, M.F. Reiser, P. Bartenstein, and M. Hacker. 2009. 18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease. Journal of Nuclear Medicine 50: 1611–1620.PubMedCrossRef
24.
go back to reference Wassélius, J.A., S.A. Larsson, and H. Jacobsson. 2009. FDG-accumulating atherosclerotic plaques identified with 18F-FDG-PET/CT in 141 patients. Molecular Imaging and Biology 11: 455–459.PubMedCrossRef Wassélius, J.A., S.A. Larsson, and H. Jacobsson. 2009. FDG-accumulating atherosclerotic plaques identified with 18F-FDG-PET/CT in 141 patients. Molecular Imaging and Biology 11: 455–459.PubMedCrossRef
25.
go back to reference Tahara, N., H. Kai, M. Ishibashi, H. Nakaura, H. Kaida, K. Baba, N. Hayabuchi, and T. Imaizumi. 2006. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. Journal of the American College of Cardiology 48: 1825–1831.PubMedCrossRef Tahara, N., H. Kai, M. Ishibashi, H. Nakaura, H. Kaida, K. Baba, N. Hayabuchi, and T. Imaizumi. 2006. Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. Journal of the American College of Cardiology 48: 1825–1831.PubMedCrossRef
26.
go back to reference Lee, S.J., Y.K. On, E.J. Lee, J.Y. Choi, B.T. Kim, and K.H. Lee. 2008. Reversal of vascular 18F-FDG uptake with plasma high-density lipoprotein elevation by atherogenic risk reduction. Journal of Nuclear Medicine 49: 1277–1282.PubMedCrossRef Lee, S.J., Y.K. On, E.J. Lee, J.Y. Choi, B.T. Kim, and K.H. Lee. 2008. Reversal of vascular 18F-FDG uptake with plasma high-density lipoprotein elevation by atherogenic risk reduction. Journal of Nuclear Medicine 49: 1277–1282.PubMedCrossRef
27.
go back to reference Chen, W., G.G. Bural, D.A. Torigian, D.J. Rader, and A. Alavi. 2009. Emerging role of FDG-PET/CT in assessing atherosclerosis in large arteries. European Journal of Nuclear Medicine and Molecular Imaging 36: 144–151.PubMedCrossRef Chen, W., G.G. Bural, D.A. Torigian, D.J. Rader, and A. Alavi. 2009. Emerging role of FDG-PET/CT in assessing atherosclerosis in large arteries. European Journal of Nuclear Medicine and Molecular Imaging 36: 144–151.PubMedCrossRef
28.
go back to reference Rudd, J.H., K.S. Myers, S. Bansilal, J. Machac, A. Rafique, M. Farkouh, V. Fuster, and Z.A. Fayad. 2007. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. Journal of the American College of Cardiology 50: 892–896.PubMedCrossRef Rudd, J.H., K.S. Myers, S. Bansilal, J. Machac, A. Rafique, M. Farkouh, V. Fuster, and Z.A. Fayad. 2007. (18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. Journal of the American College of Cardiology 50: 892–896.PubMedCrossRef
29.
go back to reference Davies, J.R., D. Izquierdo-Garcia, J.H. Rudd, N. Figg, H.K. Richards, J.L. Bird, F.I. Aigbirhio, A.P. Davenport, P.L. Weissberg, T.D. Fryer, and E.A. Warburton. 2010. FDG-PET can distinguish inflamed from non-inflamed plaque in an animal model of atherosclerosis. International Journal of Cardiovascular Imaging 26: 41–48.PubMedCrossRef Davies, J.R., D. Izquierdo-Garcia, J.H. Rudd, N. Figg, H.K. Richards, J.L. Bird, F.I. Aigbirhio, A.P. Davenport, P.L. Weissberg, T.D. Fryer, and E.A. Warburton. 2010. FDG-PET can distinguish inflamed from non-inflamed plaque in an animal model of atherosclerosis. International Journal of Cardiovascular Imaging 26: 41–48.PubMedCrossRef
30.
go back to reference Gaemperli, O., J. Shalhoub, D.R. Owen, F. Lamare, S. Johansson, N. Fouladi, A.H. Davies, O.E. Rimoldi, and P.G. Camici. 2012. Imaging intraplaque inflammation in carotid atherosclerosis with 11C-PK11195 positron emission tomography/computed tomography. European Heart Journal 33: 1902–1910.PubMedCrossRef Gaemperli, O., J. Shalhoub, D.R. Owen, F. Lamare, S. Johansson, N. Fouladi, A.H. Davies, O.E. Rimoldi, and P.G. Camici. 2012. Imaging intraplaque inflammation in carotid atherosclerosis with 11C-PK11195 positron emission tomography/computed tomography. European Heart Journal 33: 1902–1910.PubMedCrossRef
31.
go back to reference Silvola, J.M., A. Saraste, I. Laitinen, N. Savisto, V.J. Laine, S.E. Heinonen, S. Ylä-Herttuala, P. Saukko, P. Nuutila, A. Roivainen, and J. Knuuti. 2011. Effects of age, diet, and type 2 diabetes on the development and FDG uptake of atherosclerotic plaques. JACC. Cardiovascular Imaging 4: 1294–1301.PubMedCrossRef Silvola, J.M., A. Saraste, I. Laitinen, N. Savisto, V.J. Laine, S.E. Heinonen, S. Ylä-Herttuala, P. Saukko, P. Nuutila, A. Roivainen, and J. Knuuti. 2011. Effects of age, diet, and type 2 diabetes on the development and FDG uptake of atherosclerotic plaques. JACC. Cardiovascular Imaging 4: 1294–1301.PubMedCrossRef
32.
go back to reference Bybel, B., I.D. Greenberg, J. Paterson, J. Ducharme, and W.D. Leslie. 2011. Increased F-18 FDG intestinal uptake in diabetic patients on metformin: a matched case–control analysis. Clinical Nuclear Medicine 36: 452–456.PubMedCrossRef Bybel, B., I.D. Greenberg, J. Paterson, J. Ducharme, and W.D. Leslie. 2011. Increased F-18 FDG intestinal uptake in diabetic patients on metformin: a matched case–control analysis. Clinical Nuclear Medicine 36: 452–456.PubMedCrossRef
33.
go back to reference Hiroya, N. 2008. Abstract 5825: association between patterns of FDG uptake and arterial wall calcification on PET/CT and atherogenic risk factors in healthy subjects. Circulation 118: S_1012. Hiroya, N. 2008. Abstract 5825: association between patterns of FDG uptake and arterial wall calcification on PET/CT and atherogenic risk factors in healthy subjects. Circulation 118: S_1012.
34.
go back to reference Bucerius, J., R. Duivenvoorden, V. Mani, C. Moncrieff, J.H. Rudd, C. Calcagno, J. Machac, V. Fuster, M.E. Farkouh, and Z.A. Fayad. 2011. Prevalence and risk factors of carotid vessel wall inflammation in coronary artery disease patients: FDG-PET and CT imaging study. JACC. Cardiovascular Imaging 4: 1195–1205.PubMedCrossRef Bucerius, J., R. Duivenvoorden, V. Mani, C. Moncrieff, J.H. Rudd, C. Calcagno, J. Machac, V. Fuster, M.E. Farkouh, and Z.A. Fayad. 2011. Prevalence and risk factors of carotid vessel wall inflammation in coronary artery disease patients: FDG-PET and CT imaging study. JACC. Cardiovascular Imaging 4: 1195–1205.PubMedCrossRef
35.
go back to reference Tawakol, A., Z.A. Fayad, R. Mogg, A. Alon, M.T. Klimas, H. Dansky, S.S. Subramanian, A. Abdelbaky, J.H. Rudd, M.E. Farkouh, I.O. Nunes, C.R. Beals, and S.S. Shankar. 2013. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. Journal of the American College of Cardiology 62: 909–917.PubMedCrossRef Tawakol, A., Z.A. Fayad, R. Mogg, A. Alon, M.T. Klimas, H. Dansky, S.S. Subramanian, A. Abdelbaky, J.H. Rudd, M.E. Farkouh, I.O. Nunes, C.R. Beals, and S.S. Shankar. 2013. Intensification of statin therapy results in a rapid reduction in atherosclerotic inflammation: results of a multicenter fluorodeoxyglucose-positron emission tomography/computed tomography feasibility study. Journal of the American College of Cardiology 62: 909–917.PubMedCrossRef
Metadata
Title
Identification of Inflamed Atherosclerotic Lesions In Vivo Using PET-CT
Authors
Mateja Kaja Jezovnik
Nina Zidar
Luka Lezaic
Borut Gersak
Pavel Poredos
Publication date
01-04-2014
Publisher
Springer US
Published in
Inflammation / Issue 2/2014
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-013-9755-3

Other articles of this Issue 2/2014

Inflammation 2/2014 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.